Fusobacterium nucleatum, a bacterium associated with colorectal cancer, contains the fadA gene, a valuable early diagnostic biomarker. The study highlights the integration of CRISPR/Cas12a system and an improved electrochemiluminescence (ECL) biosensor for ultrasensitive detection. CRISPR/Cas-based sensors face challenges like probe entanglement and reduced enzyme efficiency, but ECL offers superior spatiotemporal control and background noise reduction, leading to enhanced sensitivity. By combining the specific CRISPR/AsCas12a with ECL, researchers have developed an amplification-free biosensing platform for precise F. nucleatum detection.
Read more from miragenews.com
